Tomas Garcia

Dr. Tomas Garcia

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MRManuel Abreu Rodríguez
Manuel Abreu Rodríguez
PSPablo Cabezas Sainz
Pablo Cabezas Sainz
TPThais Pereira-Veiga
Thais Pereira-Veiga
CFCatalina FALO
Catalina FALO
AAAlicia Abalo
Alicia Abalo
LMLaura Muinelo
Laura Muinelo
Traditionally, studies to address the characterization of mechanisms promoting tumor aggressiveness and progression have been focused only on primary tumor analyses, which could provide relevant information but have limitations to really characterize the more aggressive tumor population. To overcome these limitations, circulating tumor cells (CTCs) represent a noninvasive and valuable tool for real-time profiling of disseminated tumor cells. Therefore, the aim of the present study was to explore the value of CTC enumeration and characterization to identify markers associated with the outcome and the aggressiveness of triple-negative breast cancer (TNBC). For that aim, the CTC population from 32 patients diagnosed with TNBC was isolated and characterized. This population showed important cell plasticity in terms of expression of epithelia/mesenchymal and stemness markers, suggesting the relevance of epithelial to mesenchymal transition (EMT) intermediate phenotypes for efficient tumor dissemination. Importantly, the CTC signature demonstrated prognostic value to predict the patients’ outcome and pointed to a relevant role of tissue inhibitor of metalloproteinases 1 (TIMP1) and androgen receptor (AR) for TNBC biology. Furthermore, we also analyzed the usefulness of the AR and TIMP1 blockade to target TNBC proliferation and dissemination using in vitro and in vivo zebra fish and mouse models. Overall, the molecular characterization of CTCs from advanced TNBC patients identifies highly specific biomarkers with potential applicability as noninvasive prognostic markers and reinforced the value of TIMP1 and AR as potential therapeutic targets to tackle the most aggressive breast cancer.

20 December 2014 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
JSJuan Sendon-Lago
Juan Sendon-Lago
SSSAMUEL SEOANE
SAMUEL SEOANE
NENoemi Eiro
Noemi Eiro
MBMaria A. Bermúdez
Maria A. Bermúdez
MMManuel Macía
Manuel Macía
RPRoman Perez-Fernandez
Roman Perez-Fernandez
Introduction: The POU class 1 homeobox 1 transcription factor (POU1F1, also known as Pit-1) is expressed in the mammary gland and its overexpression induces profound phenotypic changes in proteins involved in cell proliferation, apoptosis, and invasion. Patients with breast cancer and elevated expression of Pit-1 show a positive correlation with the occurrence of distant metastasis. In this study we evaluate the relationship between Pit-1 and two collagenases: matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13), which have been related to metastasis in breast cancer. Methods: We began by transfecting the MCF-7 and MDA-MB-231 human breast adenocarcinoma cell lines with the Pit-1 overexpression vector (pRSV-hPit-1). Afterward, the mRNA, protein, and transcriptional regulation of both MMP-1 and MMP-13 were evaluated by real-time PCR, Western blot, chromatin immunoprecipitation (ChIP), and luciferase reporter assays. We also evaluated Pit-1 overexpression with MMP-1 and MMP-13 knockdown in a severe combined immunodeficiency (SCID) mouse tumor xenograft model. Finally, by immunohistochemistry we correlated Pit-1 with MMP-1 and MMP-13 protein expression in 110 human breast tumors samples. Results: Our data show that Pit-1 increases mRNA and protein of both MMP-1 and MMP-13 through direct transcriptional regulation. In SCID mice, knockdown of MMP-13 completely blocked lung metastasis in Pit-1-overexpressing MCF-7 cells injected into the mammary fat pad. In breast cancer patients, expression of Pit-1 was found to be positively correlated with the presence of both MMP-1 and MMP-13. Conclusions: Our data indicates that Pit-1 regulates MMP-1 and MMP-13, and that inhibition of MMP-13 blocked invasiveness to lung in Pit-1-overexpressed breast cancer cells.

8 April 2022 in Cells
Verified
Journal Article
Open access
PDF file
XFXiaoran Fu
Xiaoran Fu
CACristina Almenglo
Cristina Almenglo
AFAngel L. Fernández-González
Angel L. Fernández-González
JMJose Manuel Martinez-Cereijo
Jose Manuel Martinez-Cereijo
DIDiego Iglesias-Alvarez
Diego Iglesias-Alvarez
Sonia EirasSonia Eiras
Sonia Eiras
Epicardial fat thickness is associated with cardiovascular disease. Mineralocorticoid receptor antagonist (MRA), a pharmaceutical treatment for CVD, was found to have an effect on adipose tissue. Our aim was to analyse the main epicardial fat genesis and inflammation-involved cell markers and their regulation by risk factors and MRA. We included blood and epicardial or subcutaneous fat (EAT or SAT) from 71 patients undergoing heart surgery and blood from 66 patients with heart failure. Cell types (transcripts or proteins) were analysed by real-time polymerase chain reaction or immunohistochemistry. Plasma proteins were analysed by Luminex technology or enzyme-linked immunoassay. Our results showed an upregulation of fatty acid transporter levels after aldosterone-induced genesis. The MRA intake was the main factor associated with lower levels in epicardial fat. On the contrary, MRA upregulated the levels and its secretion of the anti-inflammatory marker intelectin 1 and reduced the proliferation of epicardial fibroblasts. Our results have shown the local MRA intake effect on fatty acid transporters and anti-inflammatory marker levels and the proliferation rate on epicardial fat fibroblasts. They suggest the role of MRA on epicardial fat genesis and remodelling in patients with cardiovascular disease. Translational perspective: the knowledge of epicardial fat genesis and its modulation by drugs might be useful for improving the treatments of cardiovascular disease.

30 November 2013 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
TGTomas Garcia
Tomas Garcia
OPOlga Prieto
Olga Prieto
ÁVÁngel Vázquez-Boquete
Ángel Vázquez-Boquete
FGFrancisco Gude
Francisco Gude
PVPatricia Viaño
Patricia Viaño
JAJosé R. Antúnez
José R. Antúnez

1 June 2009
Verified
Journal Article
Closed access
MSM P Santiago
M P Santiago
AVA Vázquez-Boquete
A Vázquez-Boquete
BFB Fernández
B Fernández
CMC Masa
C Masa
JAJ R Antúnez
J R Antúnez
TGTomas Garcia
Tomas Garcia

28 March 2017 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
JSJuan Sendon-Lago
Juan Sendon-Lago
SSSAMUEL SEOANE
SAMUEL SEOANE
NENoemi Eiro
Noemi Eiro
MBMaria A. Bermúdez
Maria A. Bermúdez
MMManuel Macía
Manuel Macía
RPRoman Perez-Fernandez
Roman Perez-Fernandez